Quest Diagnostics Inc
Quest Diagnostics
DGX · NYSE
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $11B
- Assets
- $16.2B
- SEC filing
- DEF 14A
- Filed
- April 6, 2026
Executive Compensation
Compensation reported for Quest Diagnostics’ named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
James E. Davis
Chairman, Chief Executive Officer And President
$15.5M
Reported total
- Salary
- $1,250,000
- Stock awards
- $8,762,861
- Incentives
- $2,205,844
- Option awards
- $2,999,873
- Other
- $279,901
Sam A. Samad
Executive Vice President And Chief Financial Officer
$4.4M
Reported total
- Salary
- $693,269
- Stock awards
- $2,190,967
- Incentives
- $710,358
- Option awards
- $749,742
- Other
- $82,805
Catherine T. Doherty
Executive Vice President, Regional Businesses
$3.6M
Reported total
- Salary
- $643,269
- Stock awards
- $1,679,674
- Incentives
- $615,184
- Option awards
- $574,876
- Other
- $49,943
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
$2.6M
Reported total
- Salary
- $568,269
- Stock awards
- $1,095,483
- Incentives
- $475,526
- Option awards
- $374,893
- Other
- $65,652
Michael E. Prevoznik
Senior Vice President And General Counsel
$2.6M
Reported total
- Salary
- $550,000
- Stock awards
- $1,132,015
- Incentives
- $438,323
- Option awards
- $387,343
- Other
- $55,912
James E. Davis
Chairman, Chief Executive Officer And President
$15.5M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed April 6, 2026.
- Salary
- $1.3M
- Stock Awards
- $8.8M
- Option Awards
- $3M
- Incentives
- $2.2M
- Other
- $280K
Historical Compensation
James E. Davis total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,250,000 | $8,762,861 | $15,498,479 |
| 2024 | $1,250,000 | $8,239,724 | $14,404,862 |
| 2023 | $1,175,000 | $7,290,745 | $12,673,834 |
Named Executive Officers
James E. Davis
Chairman, Chief Executive Officer And President
Quest Diagnostics · DGX
$15.5M
FY 2025 · DEF 14A
Sam A. Samad
Executive Vice President And Chief Financial Officer
Quest Diagnostics · DGX
$4.4M
FY 2025 · DEF 14A
Catherine T. Doherty
Executive Vice President, Regional Businesses
Quest Diagnostics · DGX
$3.6M
FY 2025 · DEF 14A
Michael E. Prevoznik
Senior Vice President And General Counsel
Quest Diagnostics · DGX
$2.6M
FY 2025 · DEF 14A
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
Quest Diagnostics · DGX
$2.6M
FY 2025 · DEF 14A
Source information
- Company
- Quest Diagnostics Inc
- Ticker
- DGX · NYSE
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- April 6, 2026
- SEC accession number
- 0001140361-26-013356
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company